Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]
Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants